The impact of genotype on outcomes in individuals with Duchenne muscular dystrophy: A systematic review. Issue 3 (8th December 2021)

• Record Type: Journal Article
• Authors: Szabo, Shelagh M.; Gooch, Katherine L.; Mickle, Alexis T.; Salhany, Renna M.; Connolly, Anne M.
• Is Part Of: Muscle & nerve. Volume 65:Issue 3(2022)
• Page Start: 266
• Page End: 277
• Publication Date: 2021-12-08
• Subjects: Duchenne muscular dystrophy -- exon skipping -- genotype -- natural history -- pathogenic variants; Neuromuscular diseases -- Periodicals; Muscles -- Periodicals; Nerves -- Periodicals; 616.74
• DOI: 10.1002/mus.27463
• Languages: English
• ISSNs: 0148-639X

Abstract

Abstract: Duchenne muscular dystrophy (DMD) is associated with progressive muscle weakness, loss of ambulation (LOA), and early mortality. In this review we have synthesized published data on the clinical course of DMD by genotype. Using a systematic search implemented in Medline and Embase, 53 articles were identified that describe the clinical course of DMD, with pathogenic variants categorizable by exon skip or stop‐codon readthrough amenability and outcomes presented by age. Outcomes described included those related to ambulatory, cardiac, pulmonary, or cognitive function. Estimates of the mean (95% confidence interval) age at LOA ranged from 9.1 (8.7‐9.6) years among 90 patients amenable to skipping exon 53 to 11.5 (9.5‐13.5) years among three patients amenable to skipping exon 8. Although function worsened with age, the impact of genotype was less clear for other outcomes (eg, forced vital capacity and left ventricular ejection fraction). Understanding the distribution of pathogenic variants is important for studies in DMD, as this research suggests major differences in the natural history of disease. In addition, specific details of the use of key medications, including corticosteroids, antisense oligonucleotides, and cardiac medications, should be reported.